Posted by Michael Wonder on 04 Oct 2020
Ruzurgi now available to Canadian Lambert-Eaton myasthenic syndrome patients
25 September 2020 - Médunik Canada is extremely pleased to announce that its new orphan disease product Ruzurgi (amifampridine) is now commercially available to Canadian patients.
Médunik Canada has retained the services of Innomar, a leading specialty pharmaceutical service and patient support program provider, for the distribution of Ruzurgi and management of its UnikAccess Patient Support Program.
Upon registering into this UnikAccess PSP, patients will receive guidance from specialized representatives to ensure sustained and continuous supply of Ruzurgi both from a distribution and financial assistance perspective.
